intellectual_property

Uniondale, N.Y. – September 16, 2026 -- Marquis Who's Who has included Monib A. Zirvi, MD, PhD, in its biographical volumes, recognizing more than two decades of work in dermatology and diagnostic genetics as a related patent dispute involving Illumina Inc. reaches final resolution.

Zirvi Has Practiced Dermatology at Summit Health Since 2004

Dr. Zirvi has served as a dermatologist with Summit Health and as an attending physician at Atlantic Health System's Overlook Medical Center since 2004, focusing on general dermatology, skin cancer detection and hair and nail disorders. Summit Health named him among its 2026 Castle Connolly Top Doctors. He is board certified by the American Board of Dermatology and holds a courtesy instructor appointment in microbiology and immunology at Weill Cornell Medicine, where he earned his MD and PhD.

Norwalk, Connecticut – September 15, 2026 -- GameChange Energy's subsidiary, GameChange Solar Corp., has filed a patent infringement lawsuit against Nextpower in the U.S. District Court for the District of Delaware, alleging unauthorized use of its high-tilt stow tracker technology.

Lawsuit targets Nextpower's tracker systems over U.S. Patent 12,449,161

The complaint states that GameChange Solar Corp. holds U.S. Patent 12,449,161, which covers the disputed high-tilt stow technology used in its single-axis solar tracker systems. GameChange contends that Nextpower's products infringe on one or more claims of this patent.

GameChange seeks injunction and monetary damages

GameChange Solar Corp. is seeking injunctive relief to halt further alleged infringement by Nextpower, along with monetary damages tied to the claim. No financial figures for damages sought were disclosed in the filing.

Tokyo -- Kaneka Corporation will appeal a September 13, 2026 ruling by the U.S. District Court for the Eastern District of New York that invalidated its U.S. Patent No. 7,829,080 covering reduced coenzyme Q10, known as ubiquinol.

New York court dismisses infringement case on enablement grounds

The court dismissed Kaneka's litigation against Cocrystal Technology (Jiaxing) Co., Ltd. and Cocrystal Health Industry (Zhejiang) Co., Ltd., ruling the '080 Patent invalid for lack of enablement. The case, filed September 13, 2026 under case number 1:23-cv-7483-SJB-SDE, had alleged that CoCrystal's ubiquinol supplements infringed claims 5 and 15 of the patent.

Grand Rapids, Mich. – – September 13, 2026 -- Shoulder Innovations, Inc. (NYSE: SI) has settled all outstanding patent litigation with Catalyst OrthoScience Inc., ending a legal dispute between the two shoulder-implant makers under confidential terms.

Shoulder Innovations resolves patent dispute with Catalyst OrthoScience under sealed terms

The settlement agreement closes all pending patent claims between Shoulder Innovations and Catalyst OrthoScience without disclosing financial or licensing terms.

CEO Rob Ball says the deal protects intellectual property tied to shoulder arthroplasty innovation

"We are pleased to have reached a resolution with Catalyst that provides an agreeable solution to this patent dispute," said Rob Ball, CEO of Shoulder Innovations. He said protecting intellectual property remains fundamental to ensuring continued investment benefits stakeholders, including surgeons and patients.

Washington, D.C. – September 11, 2026 -- NovoTech Patent Firm Founding Director Babak Akhlaghi has secured recognition from three separate intellectual property industry rankings within a single cycle, including a listing in the IAM Strategy 300 guide.

Akhlaghi earns triple recognition across global IP rankings

Akhlaghi has been named to the IAM Strategy 300, a guide identifying individuals viewed as leaders in developing and implementing IP strategies that maximize portfolio value. He was also recognized in WIPR Leaders 2026, a ranking highlighting IP professionals worldwide, and was selected to Super Lawyers for the eighth consecutive year.

Shenzhen – September 09, 2026 -- The Cologne Regional Court (Landgericht Köln, case no. 31 O 132/26) has upheld a preliminary injunction against Shenzhen Qudong Future Technology Co., Ltd. (AEKE) for infringing a registered Community design held by Shenzhen Speediance Life Tech Limited for its Gym Monster smart strength-training system.

Court confirms April injunction blocking sales in Germany

Speediance identified the disputed AEKE product at the FIBO trade show and sent a cease-and-desist letter on April 16, 2026. The following day, April 17, 2026, the Cologne Regional Court issued a preliminary injunction barring AEKE from advertising, offering, or selling the contested fitness equipment in Germany.

Shenzhen – September 09, 2026 -- The Cologne Regional Court has upheld an interim injunction against Shenzhen Qudong Future Technology Co., Ltd. ("AEKE") for infringing a registered EU design held by Shenzhen Speediance Life Tech Limited ("Speediance") for its Gym Monster smart strength training system, barring AEKE from advertising, offering or selling the disputed equipment in Germany.

Court confirms original injunction remains fully effective

Momence, Illinois – September 08, 2026 -- FutureCeuticals, Inc. and Aura Scientific have settled a patent and trademark lawsuit centered on Aura's NeuroRush® ingredient and FutureCeuticals' whole coffee fruit extract sold as CognatiQ® and NeuroFactor®.

Settlement terminates Aura's NeuroRush ingredient and validates FutureCeuticals' IP

The resolution ends production of NeuroRush® and confirms the enforceability of FutureCeuticals' intellectual property covering its whole coffee fruit extract. J. Randal Wexler, Vice President and Chief Legal Officer at FutureCeuticals, said Aura's acknowledgment of the IP's validity reinforces its market value and supports continued investment in clinical research.

Momence, Illinois – September 08, 2026 -- FutureCeuticals, Inc. and Aura Scientific have settled a patent and trademark dispute over Aura's cognitive-health ingredient "NeuroRush," ending the product and replacing it with a new distribution partnership for FutureCeuticals' whole coffee cherry extract, sold as "CognatiQ" and "NeuroFactor."

Settlement terminates NeuroRush, validates FutureCeuticals' IP portfolio

The resolution confirms the validity of FutureCeuticals' intellectual property in the cognitive health ingredient category, according to J. Randal Wexler, the company's Vice President and General Counsel. Aura's NeuroRush ingredient will be discontinued as part of the agreement.